118 related articles for article (PubMed ID: 18183354)
21. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
22. Pelvic adhesion and gonadotropin-releasing hormone analogue: effects of triptorelin acetate depot on coagulation and fibrinolytic activities.
Di Nardo MA; Annunziata ML; Ammirabile M; Di Minno MN; Ruocco AL; De Falco M; Di Lieto A
Reprod Sci; 2012 Jun; 19(6):615-22. PubMed ID: 22344729
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist.
Ezaki T; Kosaka T; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Oya M
Cancer Chemother Pharmacol; 2015 Aug; 76(2):301-6. PubMed ID: 26055219
[TBL] [Abstract][Full Text] [Related]
24. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.
Margel D; Ber Y; Peer A; Shavit-Grievink L; Pinthus JH; Witberg G; Baniel J; Kedar D; Rosenbaum E
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):177-185. PubMed ID: 32737420
[TBL] [Abstract][Full Text] [Related]
25. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
26. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
[TBL] [Abstract][Full Text] [Related]
27. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
[TBL] [Abstract][Full Text] [Related]
28. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
29. Degarelix acetate for the treatment of prostate cancer.
Klotz L
Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136
[TBL] [Abstract][Full Text] [Related]
30. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.
Triozzi PL; Bolger GB; Neidhart J; Rinehart JJ; Saleh M; Allen KO; Sellers S; Waddell MJ
Prostate; 2005 Dec; 65(4):316-21. PubMed ID: 16015596
[TBL] [Abstract][Full Text] [Related]
31. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Mehta P; Parker RI
J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
[TBL] [Abstract][Full Text] [Related]
32. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
33. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.
Miyaji Y; Saika T; Yamamoto Y; Kusaka N; Arata R; Ebara S; Nasu Y; Tsushima T; Kumon H
Urology; 2004 Jul; 64(1):128-31. PubMed ID: 15245949
[TBL] [Abstract][Full Text] [Related]
34. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
35. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
37. GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system.
Dondi D; Festuccia C; Piccolella M; Bologna M; Motta M
Oncol Rep; 2006 Feb; 15(2):393-400. PubMed ID: 16391860
[TBL] [Abstract][Full Text] [Related]
38. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
Reis LO; Denardi F; Faria EF; Silva ED
Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
[TBL] [Abstract][Full Text] [Related]
39. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
40. Testosterone Recovery after Neoadjuvant Gonadotropin-Releasing Hormone Antagonist versus Agonist on Permanent Iodine-125 Seed Brachytherapy in Prostate Cancer Patients: A Propensity Score Analysis.
Iwata T; Maruyama Y; Kawada T; Sadahira T; Katayama S; Takamoto A; Sako T; Wada K; Edamura K; Kobayashi Y; Araki M; Watanabe M; Watanabe T; Nasu Y
Acta Med Okayama; 2021 Dec; 75(6):705-711. PubMed ID: 34955538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
